Drug Discovery World

JULY 26, 2022

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The post BioNTech to deliver prestigious lecture on mRNA appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

The Pharma Data

DECEMBER 3, 2020

S-Trimer adjuvanted with GSK’s pandemic adjuvant system induced neutralizing antibody titers (seroconversion) in 100% of participants at the selected 9 µg S-Trimer dose in both adult and elderly groups, with geometric mean titers (GMT) greater than 1:1,800.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

DECEMBER 8, 2020

. “In future analyses, with more data included as it becomes available, we will investigate differences in key subgroups such as older adults, various ethnicities, doses, timing of booster vaccines, and we will determine which immune responses equate to protection from infection or disease.” © 2020 HealthDay.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

OCTOBER 12, 2022

Having spent 10 years working in the genomics field, Del Bourgo noticed manufacturers spending extensive resources on drug development without harnessing the transformative power of data. The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells.

Genome 105

Genome Genomics Medicine Development 105

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

Find Me Cure

OCTOBER 13, 2019

Drugs and therapies under study are our hope for the future of healthcare, so taking the time to learn more about them is an investment in your future health as well as the background education you need to make informed decisions about your treatment. Neratinib and tucatinib are such inhibitors being studied in metastatic breast cancer. .

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

MAY 17, 2021

The drug companies had hoped to have regulatory approval for their jab in the first half of this year, but interim results from a Phase 1/2 study, released in December 2020, had shown an “insufficient” ? In addition to the collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. This press release features multimedia. Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JANUARY 31, 2021

In its Phase 1 clinical trial, Clover’s protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either Dynavax or GlaxoSmithKline plc (GSK, London Stock Exchange: GSK) both performed well and induced high levels of neutralizing antibodies while demonstrating favorable safety and tolerability profiles.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

JULY 6, 2021

Fitusiran is an investigational, subcutaneously administered small interference RNA therapy in development for the treatment of people with hemophilia A or B, with or without inhibitors and has the potential to transform treatment as it would be the only prophylactic therapy with as few as six injections per year. FDA for ITP.

Protein 52

Protein RNA Marketing Development 52

Drug Discovery World

SEPTEMBER 6, 2022

There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 million price point per dose. Despite this the industry is still expanding.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Antibody 52

Antibody Sales Production Development 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. Immunopheresis is a ‘subtractive therapy,’ in contrast to alternative drugs that constitute ‘additive’ therapies.

Research 52

Research Drugs Protein RNA 52

Drug Discovery World

JUNE 27, 2023

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer therapies.

Regulation 52

Regulation Antibody Scientist Immune Response 52

Drug Discovery World

APRIL 12, 2023

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by CN Bio appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development 52

Development In-Vivo Drugs In-Vitro 52

Drug Discovery World

FEBRUARY 6, 2023

A key breakthrough area where big data analytics has shown tremendous scope and application is in systems biology, which has bolstered holistic drug research and development, ultimately to provide patients with access to the right therapies. Figure 2: Advanced data visualisation examples for transcriptomics data.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). RSV belongs to the family of negative-strand RNA viruses and was first identified in 1955. The global RSV vaccine and antibody market is expected to reach $2.56

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

Drug Discovery World

OCTOBER 17, 2023

DDW Editor Reece Armstrong speaks to Benedikt Nilges , Head of Technology and Data Analytics at OMAPiX about spatial biology’s use in drug discovery and bettering our understanding of disease. This limits its efficacy in later stages of drug development or in the discovery and characterisation of biomarkers.

Gene Expression 52

Gene Expression Drugs Protein Gene 52

The Pharma Data

JANUARY 21, 2021

.” But the Pfizer and Moderna vaccines are designed to not only target the spike protein, but to promote the creation of antibodies that will attack it in several different ways, Salvatore said. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge.

Vaccination 52

Vaccination Vaccine RNA Clinical Trials 52

Drug Discovery World

JANUARY 4, 2023

The researchers used high-dimensional immune profiling and single-cell RNA sequencing to study how the TIME is affected by a variety of immunotherapies. They identified specific immune checkpoint proteins, 41BB and LAG, that were highly expressed in exhausted T cells. .

Immune Response 52

Immune Response Protein Research Antibody 52

The Pharma Data

JUNE 26, 2021

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. These results were published in Nature in July 2020.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 8, 2020

The safety and efficacy of vaccines, including any potential vaccine for COVID-19, is reviewed and determined by expert regulatory agencies around the world, such as the United States Food and Drug Administration (FDA). For more information, visit www.merck.com and connect with us on Twitter , Facebook , Instagram , YouTube and LinkedIn.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. An often-overlooked component of adaptive immunity is T cell-mediated immunity.

Protein 98

Protein RNA Antibody Production 98

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Non-COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

United States Food and Drug Administration. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. For more information, visit.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. Since then, the drug has been used off-label in breast cancer and other types of cancer. Langer, now a David H.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

Pfizer

NOVEMBER 2, 2022

The first participant has been dosed in a Phase 1 trial evaluating the safety, tolerability, and immunogenicity of a nucleoside-modified RNA (modRNA)-based combination vaccine approach. The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92